

# Julia Hoefler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7725898/publications.pdf>

Version: 2024-02-01

16  
papers

773  
citations

623699

14  
h-index

996954

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1561  
citing authors

#	ARTICLE	IF	CITATIONS
1	The "rejuvenating factor"™ TIMP <sup>2</sup> is detectable in human blood components for transfusion. <i>Vox Sanguinis</i> , 2021, 116, 533-539.	1.5	3
2	Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. <i>Oncogene</i> , 2021, 40, 3087-3100.	5.9	18
3	The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 927-938.	7.0	128
4	The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2722-2731.	4.1	32
5	The "Aging Factor"•Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor's Age. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 402.	3.4	26
6	SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2016, 14, 574-585.	3.4	36
7	Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. <i>Oncotarget</i> , 2016, 7, 59781-59794.	1.8	52
8	Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR <sub>2</sub> . <i>EMBO Molecular Medicine</i> , 2014, 6, 810-820.	6.9	29
9	SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 175-187.	3.1	34
10	PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. <i>Oncotarget</i> , 2014, 5, 12043-12056.	1.8	29
11	Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205. <i>American Journal of Pathology</i> , 2012, 181, 2188-2201.	3.8	225
12	PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21. <i>American Journal of Pathology</i> , 2012, 180, 2097-2107.	3.8	72
13	Soluble gp130 Regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner. <i>Journal of Urology</i> , 2011, 186, 2107-2114.	0.4	15
14	The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice. <i>PLoS ONE</i> , 2010, 5, e8722.	2.5	45
15	The thyromimetic T-0681 protects from atherosclerosis. <i>Journal of Lipid Research</i> , 2009, 50, 938-944.	4.2	29
16	Critical Role of Androgen Receptor Level in Prostate Cancer Cell Resistance to New Generation Antiandrogen Enzalutamide. <i>Endocrine Abstracts</i> , 0, , .	0.0	0